tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

SPRY Stock Latest News

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
Press ReleasesARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
9d ago
SPRY
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
PremiumPress Releases
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
10d ago
SPRY
ARS Pharmaceuticals submits sNDA to FDA for neffy 1 mg
PremiumThe Fly
ARS Pharmaceuticals submits sNDA to FDA for neffy 1 mg
10d ago
SPRY
ARS Pharmaceuticals launches pre-ordering services for neffy
PremiumThe Fly
ARS Pharmaceuticals launches pre-ordering services for neffy
16d ago
SPRY
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
PremiumPress Releases
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
25d ago
SPRY
ARS Pharmaceuticals announces EC approval for EURneffy
PremiumThe FlyARS Pharmaceuticals announces EC approval for EURneffy
25d ago
SPRY
Medtronic, Palo Alto Networks report quarterly beats: Morning Buzz
Premium
The Fly
Medtronic, Palo Alto Networks report quarterly beats: Morning Buzz
1M ago
AS
BA
Vornado upgraded, JPMorgan downgraded: Wall Street’s top analyst calls
Premium
The Fly
Vornado upgraded, JPMorgan downgraded: Wall Street’s top analyst calls
1M ago
AR
AMD
Cantor starts ARS at Overweight, sees 111% potential upside
PremiumThe Fly
Cantor starts ARS at Overweight, sees 111% potential upside
1M ago
SPRY
ARS Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
ARS Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
1M ago
SPRY
Starbucks picks new CEO, Google unveils Pixel 9: Tuesday Buzz
PremiumThe Fly
Starbucks picks new CEO, Google unveils Pixel 9: Tuesday Buzz
1M ago
GM
HD
Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz
PremiumThe Fly
Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz
1M ago
CG
HD
Raymond James upgrades ARS Pharmaceuticals to Strong Buy on tailwinds
PremiumThe FlyRaymond James upgrades ARS Pharmaceuticals to Strong Buy on tailwinds
1M ago
SPRY
ARS Pharmaceuticals’ Neffy Aims for Global Market Impact
Premium
Company Announcements
ARS Pharmaceuticals’ Neffy Aims for Global Market Impact
1M ago
8K
SPRY
ARS Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
Premium
The Fly
ARS Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
1M ago
SPRY
ARS Pharmaceuticals price target raised to $20 from $19 at Leerink
PremiumThe Fly
ARS Pharmaceuticals price target raised to $20 from $19 at Leerink
1M ago
SPRY
Aquestive Therapeutics price target raised to $15 from $13 at Oppenheimer
PremiumThe Fly
Aquestive Therapeutics price target raised to $15 from $13 at Oppenheimer
1M ago
AQST
SPRY
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
PremiumPress Releases
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
1M ago
SPRY
ARS Pharmaceuticals receives FDA approval of neffy
PremiumThe Fly
ARS Pharmaceuticals receives FDA approval of neffy
1M ago
SPRY
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
PremiumPress ReleasesARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
1M ago
SPRY
ARS Pharmaceuticals reports Q2 EPS (13c), consensus (12c)
Premium
The Fly
ARS Pharmaceuticals reports Q2 EPS (13c), consensus (12c)
1M ago
SPRY
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
Premium
Press Releases
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
1M ago
SPRY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >